|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM165427825 |
| 003 |
DE-627 |
| 005 |
20250207151841.0 |
| 007 |
tu |
| 008 |
231223s2007 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0552.xml
|
| 035 |
|
|
|a (DE-627)NLM165427825
|
| 035 |
|
|
|a (NLM)16982214
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Martínez-Lorenzo, María José
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL
|
| 264 |
|
1 |
|c 2007
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.02.2007
|
| 500 |
|
|
|a Date Revised 21.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The infiltration and accumulation of T cells in the rheumatoid arthritis (RA) synovial fluid (SF) are hallmarks of disease. We aimed to assess the functional relevance of FasL and of APO2L/TRAIL in the persistence of T cells in the rheumatoid SF. We have analyzed the expression of the activation markers HLA-DR and CD69 and also of the death receptor Fas/CD95 and death ligands FasL or APO2L/TRAIL in CD3+ lymphocytes from SF of 62 RA patients, together with their sensitivity to anti-Fas mAb or to rAPO2L/TRAIL, using as controls T lymphocytes present in SF of 20 patients with traumatic arthritis. T lymphocytes infiltrated in SF of RA patients have a chronically activated phenotype, but they are resistant to Fas-induced toxicity. However, they are more susceptible to rAPO2L/TRAIL than T cells in the SF of traumatic arthritis patients. In addition, we found very low amounts of bioactive FasL and APO2L/TRAIL associated with exosomes in SF from RA patients as compared with SF from traumatic arthritis patients. The observation on the sensitivity of RA SF T cells to rAPO2L could have therapeutic implications because bioactive APO2L/TRAIL could be beneficial as a RA treatment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Differentiation, T-Lymphocyte
|2 NLM
|
| 650 |
|
7 |
|a CD3 Complex
|2 NLM
|
| 650 |
|
7 |
|a CD69 antigen
|2 NLM
|
| 650 |
|
7 |
|a Fas Ligand Protein
|2 NLM
|
| 650 |
|
7 |
|a HLA-DR Antigens
|2 NLM
|
| 650 |
|
7 |
|a Lectins, C-Type
|2 NLM
|
| 650 |
|
7 |
|a TNF-Related Apoptosis-Inducing Ligand
|2 NLM
|
| 650 |
|
7 |
|a fas Receptor
|2 NLM
|
| 700 |
1 |
|
|a Anel, Alberto
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Saez-Gutierrez, Berta
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Royo-Cañas, María
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bosque, Alberto
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Alava, María Angeles
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Piñeiro, Andrés
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lasierra, Pilar
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Asín-Ungría, Jaime
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Larrad, Luis
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 122(2007), 1 vom: 15. Jan., Seite 28-40
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:122
|g year:2007
|g number:1
|g day:15
|g month:01
|g pages:28-40
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 122
|j 2007
|e 1
|b 15
|c 01
|h 28-40
|